Clinical Trials Browser

Phase 3 × Recruiting × tislelizumab × Clear all

NCT06745908 2026-05-05

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07416474 2026-04-20

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07315750 2026-01-21

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT07170995 2025-11-18

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06793917 2025-07-20

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06598527 2025-05-29

SACTION2401

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06332274 2025-05-13

UMBRELLA

Phase 3 Recruiting

GastrointestinalSarcomaThoracic

Colonic Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT06416410 2025-04-04

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Phase 3 Recruiting

Advanced Non-squamous Non-small-cell Lung Cancer

NCT06258811 2025-03-13

Neoadjuvant Immunochemotherapy for LAOSCC

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05919030 2024-11-14

A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

Phase 3 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06520683 2024-11-07

SMALLER

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06383780 2024-07-16

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT06441110 2024-06-04

Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Phase 3 Recruiting

Urinary Bladder Neoplasms, Motor Activity, Neoplasm Recurrence, Local

NCT06017583 2023-10-11

Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05342792 2022-04-25

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Phase 3 Recruiting

Nasopharyngeal Carcinoma